Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 21

PMID 35311140

Authors

Vincenzo Di Nunno

Enrico Franceschi

Alicia Tosoni

Lidia Gatto

Stefania Bartolini

Alba Ariela Brandes

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is an aggressive tumor and is associated with a dismal prognosis. The availability of few active treatments as well as the inexorable recurrence after surgery are important hallmarks of the disease. The biological behavior of glioblastoma tumor cells reveals a very complex pattern of genomic alterations and is partially responsible for the clinical aggressiveness of this tumor. It has been observed that glioblastoma cells can recruit, manipulate and use other cells including neurons, glial cells, immune cells, and endothelial/stromal cells. The final result of this process is a very tangled net of interactions promoting glioblastoma growth and progression. Nonetheless, recent data are suggesting that the microenvironment can also be a niche in which glioblastoma cells can differentiate into glial cells losing their tumoral phenotype. Here we summarize the known interactions between micro-environment and glioblastoma cells highlighting possible therapeutic implications.

Citing Articles

Recapitulating Glioma Stem Cell Niches Using 3D Spheroid Models for Glioblastoma Research.

Jo H, Lee S, Kim M, Park S, Lee S Biosensors (Basel). 2024; 14(11).

PMID: 39589998 PMC: 11592235. DOI: 10.3390/bios14110539.

First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).

Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M Front Immunol. 2024; 15:1404861.

PMID: 39192978 PMC: 11347333. DOI: 10.3389/fimmu.2024.1404861.

Neuroinflammation in Glioblastoma: Progress and Perspectives.

Li X, Gou W, Zhang X Brain Sci. 2024; 14(7).

PMID: 39061427 PMC: 11274945. DOI: 10.3390/brainsci14070687.

Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.

Doron O, Wong T, Ablyazova F, Singha S, Cavallaro J, Ben-Shalom N J Neurooncol. 2024; 168(2):225-235.

PMID: 38664311 PMC: 11147875. DOI: 10.1007/s11060-024-04647-w.

Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers.

Lan Z, Li X, Zhang X Int J Mol Sci. 2024; 25(5).

PMID: 38474286 PMC: 10931698. DOI: 10.3390/ijms25053040.

References

Lo H . Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets. 2010; 10(8):840-8. PMC: 3615246. DOI: 10.2174/156800910793357970. View

Gorlach A, Dimova E, Petry A, Martinez-Ruiz A, Hernansanz-Agustin P, Rolo A . Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?. Redox Biol. 2015; 6:372-385. PMC: 4565025. DOI: 10.1016/j.redox.2015.08.016. View

Piccirillo S, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A . Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene. 2009; 28(15):1807-11. DOI: 10.1038/onc.2009.27. View

Di Nunno V, Franceschi E, Gatto L, Bartolini S, Brandes A . Predictive markers of immune response in glioblastoma: hopes and facts. Future Oncol. 2020; 16(15):1053-1063. DOI: 10.2217/fon-2020-0047. View

van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J . INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; 22(5):684-693. PMC: 7229258. DOI: 10.1093/neuonc/noz222. View

Krusche B, Ottone C, Clements M, Johnstone E, Goetsch K, Lieven H . EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells. Elife. 2016; 5. PMC: 4924994. DOI: 10.7554/eLife.14845. View

Teeling J, Perry V . Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience. 2008; 158(3):1062-73. DOI: 10.1016/j.neuroscience.2008.07.031. View

Seifert S, Sontheimer H . Bradykinin enhances invasion of malignant glioma into the brain parenchyma by inducing cells to undergo amoeboid migration. J Physiol. 2014; 592(22):5109-27. PMC: 4259546. DOI: 10.1113/jphysiol.2014.274498. View

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R . Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res. 2011; 17(13):4296-308. DOI: 10.1158/1078-0432.CCR-10-2557. View

10.

Burger P, Dubois P, Schold Jr S, SMITH Jr K, ODOM G, Crafts D . Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg. 1983; 58(2):159-69. DOI: 10.3171/jns.1983.58.2.0159. View

11.

Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y . Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014; 110(10):2560-8. PMC: 4021514. DOI: 10.1038/bjc.2014.162. View

12.

Levin V, Chan J, Datta M, Yee J, Jain R . Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. J Neurooncol. 2017; 134(2):325-330. DOI: 10.1007/s11060-017-2528-3. View

13.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View

14.

Piccirillo S, Dietz S, Madhu B, Griffiths J, Price S, Collins V . Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer. 2012; 107(3):462-8. PMC: 3405212. DOI: 10.1038/bjc.2012.271. View

15.

Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson S, Li B . Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410(6829):701-5. DOI: 10.1038/35070587. View

16.

Vehlow A, Cordes N . Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta. 2013; 1836(2):236-44. DOI: 10.1016/j.bbcan.2013.07.001. View

17.

Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, Ogawa A . Change of oxygen pressure in glioblastoma tissue under various conditions. J Neurooncol. 2002; 58(1):47-52. DOI: 10.1023/a:1015832726054. View

18.

Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A . The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res. 2015; 35(3):1743-8. View

19.

Brooks L, Clements M, Burden J, Kocher D, Richards L, Devesa S . The white matter is a pro-differentiative niche for glioblastoma. Nat Commun. 2021; 12(1):2184. PMC: 8042097. DOI: 10.1038/s41467-021-22225-w. View

20.

Quail D, Bowman R, Akkari L, Quick M, Schuhmacher A, Huse J . The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016; 352(6288):aad3018. PMC: 5450629. DOI: 10.1126/science.aad3018. View